MD Anderson presents promising results from HER2-targeted therapy and other cancer breakthroughs at AACR 2025
Researchers from The University of Texas MD Anderson Cancer Center shared the latest breakthroughs in cancer care, research and prevention today at the American Association for Cancer Research (AACR) Annual Meeting 2025.
Plenary presentation features positive results in HER2-mutant lung cancer
John Heymach, M.D., Ph.D., chair of Thoracic/Head and Neck Medical Oncology, presented data showing that zongertinib, a HER2-targeted therapy, demonstrated promising results in HER2-mutant lung cancer, prompting a priority review by the FDA and a Phase II trial comparing it to the current standard of care (Abstract CT050).
Read more in the full press release.
Minisymposia presentations highlight cancer breakthroughs
Chad Tang, M.D., associate professor of GU Radiation Oncology, presented on a study showing that metastasis-directed radiation therapy can help patients avoid systemic therapies without compromising outcomes and that a novel ctDNA assay detecting molecular residual disease is a useful personalized prognostic biomarker for response (Abstract CT132).
Blessie Nelson, M.B.B.S., assistant professor of General Oncology, presented on metaplastic breast cancer, a rare and invasive breast cancer subtype, analyzing 258 cases to characterize genomic alterations and mutations that can lead to targeted therapies (Abstract 3746).
Alexander Biederstädt, M.D., presented on using CRISPR genetic screens of natural killer (NK) cells to identify novel regulators of NK cell function that can be targeted to optimize chimeric antigen receptor (CAR) NK cell therapies (Abstract 3763).
Simon Heeke, Ph.D., assistant professor of Thoracic Head and Neck Medical Oncology, presented on the use of blood-based prognostic biomarker to improve risk stratification in patients with EGFR-mutant non-small cell lung cancer (Abstract 3776).
Enrico Gurreri, M.D., research assistant of Genitourinary Medical Oncology, presented research on genomic instability as a driver of treatment resistance and tumor progression in patients with KRAS-mutant pancreatic cancer (Abstract 3824).
More posts featuring MD Anderson Cancer Center.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023